|Home | About | Journals | Submit | Contact Us | Français|
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Fatigue in COPD impairs functional status; however there are few studies examining mechanistic pathways of this symptom. The aims of this study are to compare fatigue between COPD patients and healthy age-matched subjects, and to identify predictors of fatigue in COPD.
Seventy four COPD patients, mean age 69.9 (49-87) yrs, mean (SD) % predicted FEV1 46.5 (20.0) % and FEV1/FVC ratio 0.45 (0.13) and 35 healthy subjects, mean age 67.1 (50-84) yrs completed the Multidimensional Fatigue Inventory (MFI 20). Patients' assessment included Depression (HADS), lung function, BMI, muscle strength, incremental shuttle walk test (ISWT), exercise oxygen saturation (SpO2), Borg breathlessness (CR-10) and exertion (RPE). Serum level of Interleukin 6 (IL-6) was recorded. Differences in MFI 20 between groups were examined and predictors of fatigue identified using logistic regression.
Significant differences (p < 0.01) were found between the COPD and healthy subjects for all MFI 20 dimensions. There were significant differences when classified according to GOLD and dyspnoea stages for selected dimensions only. Predictors of General Fatigue were depression, muscle strength and end SpO2 (R2 = .62); of Physical Fatigue: depression, % predicted FEV1, ISWT and age (R2 = .57); Reduced Activity: % predicted FEV1, BMI and depression (R2 = .36); Reduced Motivation: RPE, depression and end SpO2 (R2 = .37) and Mental Fatigue: depression and end SpO2 (R2 = .38).
All dimensions of fatigue were higher in COPD than healthy aged subjects. Predictive factors differ according to the dimension of fatigue under investigation. COPD-RF is a multi component symptom requiring further consideration.
Fatigue, as a symptom in chronic obstructive pulmonary disease (COPD) may have diverse manifestations, such as physical or mental tiredness, loss of attention, concentration or motivation [1,2]. It is an important [3-5] and highly prevalent symptom [6,7] with data from one study suggesting that 90% of COPD patients may report fatigue . Although fatigue in COPD is acknowledged by clinicians, it is often neglected. In fact, compared with cancer the predictors and patho-mechanisms of fatigue are poorly evaluated in COPD and there is a lack of understanding regarding the management of fatigue. There are evident associations between fatigue, impaired quality of life and increased depression [8-10]. Furthermore, fatigue and dyspnoea in COPD, whilst related, appear to be separate entities [11,4]. Using the FACIT-fatigue uni-dimensional scale, no association between disease severity and fatigue is noted . However, the Multidimensional Fatigue Inventory (MFI 20) , which is well validated in COPD and shows moderate relationships with airflow obstruction [10,13]. The MFI 20 provides a multi-dimensional evaluation of fatigue, enabling investigation of the different components. Since several factors are likely to be involved in the development of COPD related fatigue (COPD-RF), the use of a multi-dimensional tool enables further elucidation of mechanistic pathways. For instance, whilst hypoxia and hypoxaemia, impaired fat free mass and loss of fatigue resistant muscle fibres are associated with fatigue , it is not known if the variables relate to physical or mental fatigue specifically. In healthy subjects, acute exercise fatigue is associated with raised levels of Interleukin 6 (IL6) [15,16]; possibly, this pathway is important in the development of COPD-RF . There are few studies that comprehensively investigate predictors of the different domains of fatigue in COPD. This study attempts to draw together the psychological and physiological aspects of fatigue to develop working models of COPD-RF, by using comparative data from healthy age-matched subjects. This research hypothesises that increases in each component of fatigue in COPD may be predicted by differing factors. The aims of this study were firstly, to provide comparative data of fatigue, using the MFI 20, between COPD patients and healthy elderly subjects and secondly, to explore possible predictors of fatigue components of the MFI 20.
Full ethical consent was obtained for this cross sectional study from the Royal Marsden Local Research Ethics Committee (London, UK). Patients and control subjects gave written informed consent prior to entering the study.
A total of 80 COPD patients (defined as FEV1/FVC ratio < 0.7 with a general practitioner or chest physician diagnosis) and 37 healthy elderly subjects were recruited to the study. Patients with stable COPD (no exacerbation or change of medication in last 6 weeks) were recruited from the chest clinic of St. George's Hospital. Figure Figure11 shows the patient recruitment flow chart. Healthy subjects were recruited from the staff and volunteers of St. George's University, St. George's Hospital and from an Open University group. Absence of airway obstruction was confirmed by spirometry. Additionally, patients and subjects were excluded if they had a history of significant inflammatory co-morbidities such as carcinoma, rheumatoid arthritis or stroke, unstable angina, a diagnosis of psychiatric disorders, or mobility limiting conditions.
Fifty nine patients included in the study attended the hospital for a baseline morning assessment of approximately 2.5 - 3.5 hours (transport available). Assessment was carried out over two days if necessary, for instance, when the patient was too tired to continue. A further 15 housebound severe COPD patients were unable to attend the hospital for assessment; for these patients an adapted home assessment was provided.
Fatigue was assessed in the morning prior to other assessments in patients and healthy subjects using MFI 20, a 20-item self-report validated instrument [12,18]. This tool has been previously used in COPD population and it is recommended as an outcome measure in clinical settings . The questionnaire asks subjects to describe how they have been feeling lately. For issues of clarity this was specified as "within the last two weeks". The tool consists of five dimensions covering General Fatigue (GF), Physical Fatigue (PF), Reduced Activity (RA), Reduced Motivation (RM) and Mental Fatigue (MF). Each dimension has 4 items, each item scored from 1-5 with higher scores representing greater levels of fatigue.
All participants completed the Hospital Anxiety and Depression Scale (HADS). The HADS is a questionnaire designed to measure depressive moods and anxiety separately . A score of 11 or higher indicates probable presence of the mood disorder, but it is not a synonymous of the diagnosis.
Baseline breathlessness level was assessed using the Medical Research Council Dyspnoea Grade (MRC) .
Health Related QoL was measured using Saint George's Respiratory Questionnaire (SGRQ) .
For all participants height (cm) and weight (kg) were measured. Body Mass (BMI) and Fat Free Mass (FFMI) indices were determined from body composition measurements using a non-invasive bioelectrical impedance technique (Body composition analyser, Tanita Ltd BC-418MA, UK). Baseline FEV1 and FVC were assessed using a spirometer Micro Plus MS03 (Micro Medical Ltd, Rochester UK) and according to BTS recommendations . GOLD classification was used to determine patients' airway obstruction severity .
For all participants quadriceps maximal torque was measured using a "Cybex Norm™ Testing and Rehabilitation System". The protocol consisted of 1 minute of consecutive concentric knee extensions and flexions, performed maximally at an angular velocity of 60°/sec, following a 10-repetition trial. The break between the trial and actual test was 20 seconds. Maximum torque was recorded as the best attempt during 1 minute isokinetic work of the dominant side (FtLbs) and as FtLbs/subject bodyweight (lb) *100.
For patients only, maximal exercise tolerance was assessed using the Incremental Shuttle Walking Test (ISWT), an incremental, externally paced exercise capacity test conducted according to standardised procedure . Endurance exercise tolerance was then assessed using the Endurance Shuttle Walking Test (ESWT) . Prior to and after each test percutaneous arterial oxygen saturation (SpO2) and heart rate were measured using a pulse oxymeter (Pulsox-3i-Konika Minolta, Singapore) applied to the finger. Borg CR 10 (Dyspnoea assessment) and Borg Rating of Perceived Exertion (RPE) scales were scored after each test [27,28].
For patients only, a fasting, resting venous blood sample was obtained from the median cubital vein and Interleukin-6 (IL-6) was measured from serum. Blood samples were centrifuged within 2 hours of collection and serum was stored at -20°C until assay. The analysis was performed on an Immulite® 1000 automated analyser (Siemens Medical Solutions Diagnostics, formally Euro/DPC Ltd Gwynedd Wales, UK). The limit of detection for serum IL-6 was 0.2 pg/mL-1. Patients' haemoglobin (Hb) levels were determined from their ear lobe capillary blood sample, using blood gas/electrolyte analyser (model 5700; Instrumentation Laboratory, Lexington MA). Anaemia was defined according to WHO criteria .
The 15 home assessments were as described above with the exception of measures of exercise tolerance, muscle strength and blood sampling.
Summary statistics of the healthy subjects' and COPD patients' characteristics were reported. Independent sample t-tests or Mann-Whitney tests as appropriate were used to test for differences between the patients and the healthy subjects. The Kruskal-Wallis test was used to determine differences between fatigue dimensions according to the MRC score and GOLD classification with the significance level set at α = 0.05. When significant differences were found, post hoc analysis was carried out using Mann-Whitney tests with Bonferroni correction. The data used to measure fatigue are not metric and therefore multiple linear regression techniques are inappropriate. Due to the small number of subjects, logistic rather than ordinal regression was chosen to identify predictors of the 5 dimensions of fatigue; a backward elimination method was used. Therefore for each dimension of fatigue, a binominal category was defined using a cut-off point of the highest value of fatigue in the healthy subjects. Values above this point were considered as fatigued and values below as not fatigued. Explanatory variables that were independent of one another, according to appropriate correlation tests were included in the initial regression models. Other, clinically relevant variables, as identified from literature [9,10,13,14,17,30,31] were also included. The final models, presented here, are those where all the remaining independent variables are statistically significant predictors of the fatigue dimension under consideration and which have the highest R2 value. The data from 15 home assessments were excluded due to the modified assessment. All analyses were performed using SPSS 15.
Seventy four mild-to-severe COPD patients and 35 healthy subjects completed all assessments.
There were no significant differences in fatigue according to gender in either the COPD (52 male vs. 22 female) or the healthy group (12 male vs. 23 female). Median scores for COPD patients were significantly higher than those of the healthy subjects in all dimensions of MFI 20. Table Table11 shows the scores for fatigue and other variables and differences between COPD patients and the healthy subjects.
Statistically significant differences in fatigue when categorised according to the GOLD and MRC dyspnoea classifications were evident for selected dimensions of MFI 20 only (see figure figure22 and figure figure33).
Regression analysis was performed on full data available from 59 patients (40 male) aged 68.7 (8.1), mean (SD) % predicted FEV1 48.2 (20.9) and FEV1/FVC ratio 0.45 (0.13). Clinically relevant variables were identified based on literature and results of correlations with fatigue dimensions. Following the initial regression analyses nine possible predictors were identified: % predicted FEV1, depression, muscle torque, ISWT, end exercise SpO2, IL6, Borg RPE, BMI, age. The final decision on which variables to include was determined by clinical relevance and by the best possible model of predictive variables.
The mean (SD) haemoglobin level was 15.6 (2.9) g/dL in male and 14.6 (1.6) g/dL in female patients. Only 2 patients had values below normal. Anaemia was therefore not a feature of the patient population and thus was not included in the regression analysis. There were high correlations between anxiety and depression, BMI and FFMI, ISWT and ESWT. Hence anxiety, FFMI and ESWT were not entered into the regression as independent variables as the others were considered more important clinically.
MRC score as a measure of dyspnoea was initially considered as a predictor of fatigue. Although expected from literature and from the results presented in figure figure3,3, it was not a significant predictor for any of fatigue dimension and it was eventually excluded in the final regression process. Measures of quality of life (SGRQ) were collected to enable baseline characterisation of the patients. Although quality of life has been shown to be associated with fatigue in previous studies [8,9], direction of causality is unknown. It was felt that fatigue was more likely to be a mediator of impaired quality of life than the other direction, thus SGRQ data were not included in the regression as independent predictors.
For GF the following 5 variables were entered: depression, muscle torque, % predicted FEV1, end SpO2, IL 6; for PF: depression, ISWT, % predicted FEV1 and age; for RA: depression, ISWT, % predicted FEV1 and BMI; for RM: depression, end Borg RPE and end SpO2 and for MF: depression, IL6 and end SpO2. Table Table2,2, ,3,3, ,4,4, ,55 and and66 give the results of the logistic regression analyses. Table Table22 shows, for instance, that the significant predictors of GF (as measured by Wald statistic) are depression, muscle torque and end exercise SpO2. For every increase of 1 in the depression score a patient is approximately 1.5 times more likely to be fatigued and for lower end exercise SpO2 there is a slightly higher chance of being fatigued; similarly lower muscle strength is associated with higher risk of fatigue.
Fatigue score was significantly higher in COPD compare to control group for all dimensions of MFI 20. After stratification for MRC and GOLD classifications there were significant differences only for selected dimensions of fatigue. Fatigue, when considered as a multi-component construct was explained by a different combination of variables.
The results from this study show that subjective fatigue measured with MFI 20 was significantly higher in the COPD group than in healthy elderly people. Previous work supports these findings [8,32], which suggests that the increased fatigue reflects disease entity and may therefore be considered as COPD-RF and it should be properly addressed in clinical practice. In contrast to other authors  differences were found in fatigue according to GOLD staging, however these differences were specific for selected dimensions of fatigue only. The difference in findings likely reflects the different fatigue tools used, with this study using a multi-dimensional tool compared with the FACIT-fatigue, a uni-dimensional tool.
In line with this, it is demonstrated here that differing fatigue dimensions can be explained by different physiological and psychological variables associated with COPD and only depression was a common predictor. Although according to MRC dyspnoea classification there were significant differences for Reduced Activities, General and Physical Fatigue, the regression analysis excluded dyspnoea score as a possible predictive variable of fatigue. Importantly, the cohort used in regression study differ from one used in MRC classification analysis and data from home-assessed most severe patients may have been more insightful. Previous studies also showed associations between dyspnoea and fatigue [8,30,31]. Nonetheless, fatigue and dyspnoea are both subjective symptoms of COPD and some of the patho-mechanisms of fatigue may be common for those of dyspnoea. Therefore, this may explain the close association between these symptoms. Since fatigue is not routinely assessed in current clinical practice, the models from this study may help to identify patients who are at risk of being fatigued and develop effective fatigue management strategies. Furthermore, the regression analyses revealed that each component could be explained by different variations. Hence, the multi-rather than uni-dimensional assessment should be considered. Over half of the variation in general fatigue was explained by a combination of depression, exercise de-saturation and muscle strength. These data then provide further support for the role of muscle training, depression management and use of supplementary oxygen in COPD. In this present study exercise de-saturation was also a significant predictor for the MFI 20 Reduced Motivation component. For Reduced Motivation; depression, post exercise saturation and exertion explained a little less than 40% of the variation. This component includes items such as 'I dread having to do things' and 'I don't feel like doing anything'. Low oxygen levels may be associated with changes in cognitive function [33,34] and stimulate affective areas of the brain, mainly in the frontal lobe, which is associated with motivational process [35,36]. Feasibly, the administration of oxygen during exertion may be associated with lower fatigue levels and enhanced motivation. To date this application of oxygen has not been explored.
For physical fatigue the best model, a combination of depression, lung function and exercise tolerance, explained 57% of the variation. This provides some explanation as to how therapies that improve exercise tolerance and depression can have an impact on fatigue in COPD . Muscle strength and exercise tolerance were significant predictors for general and physical fatigue, respectively. These two variables were highly correlated and therefore only one was used in the regression analysis. Muscle weakness and reduced exercise tolerance are well recognised in the COPD population [38,39] and may be important factors influencing COPD RF.
Around 40% of the variation in Reduced Activity was explained by the combination of lung function, BMI and depression. In this instance a higher BMI was associated with greater fatigue. This probably reflects the U-shaped curve nature of the association between BMI and outcomes, both low and high BMI is generally associated with poorer outcome . Nutritional status remains an important therapeutic outcome in the management of COPD. Furthermore, in physically related dimensions of fatigue the severity of airway obstruction explained a significant amount of the variance, suggesting that treatments which affect airflow obstruction may also benefit the perception of physical fatigue. For mental fatigue few COPD patients were identified as fatigued and the results for this component should be treated with caution.
Anaemia may be one of the causes of fatigue and can be present in COPD patients ; however, haemoglobin levels were generally within the normal range in the cohort, thus this factor could not be included in this analysis. Nevertheless, it is clear from this study, that COPD RF remains a significant problem even in patients with moderate disease and no anaemia. Although some variables were not included in the final regression model, they may still play a role in the development of COPD RF. For example, there was a strong correlation between anxiety and depression, but it was decided only to include depression. Similarly, ESWT was strongly related to ISWT but only the maximal test was included. Although IL6 was considered a possible predictor, none of the final regression models included it, which may be due to its correlation with both muscle strength and walking distance  or reflects the need for other measures such as receptors.
Previous studies using a multiple regression identified depression as a predictive variable of uni-dimansional fatigue in COPD [8,30]. However, findings here reveal that depression is a predictor for all dimensions of fatigue.
This study shows that all dimensions of fatigue are greater in COPD than in healthy people of a similar age range. Increased fatigue in this population is therefore a feature of COPD and not of age per se. COPD-RF is a multi component construct and as such different aspects of fatigue are influenced by different clinical manifestations. Comprehensive treatment of COPD-RF includes management of depression, muscle weakness, optimisation of BMI and exercise de-saturation levels. In contrast to other authors it was found that fatigue differs according to GOLD staging, however this is relevant only for Physical Fatigue and Reduced Activity. This study goes some way towards explaining the mechanistic pathway of COPD-RF and provides information to target hitherto neglected treatments.
BTS: British Thoracic Society; COPD: Chronic Obstructive Pulmonary Disease; COPD-RF: Chronic Obstructive Pulmonary Disease Related Fatigue; CR 10: Borg Dyspnoea Assessment Scale; ESWT: Endurance Shuttle Walking Test; FEV1: Forced Expiratory Volume in One Second; FtLb: Foot-Pound Force; FVC: Forced Vital Capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; HADS: Hospital Anxiety and Depression Scale; Hb: Haemoglobin; IL 6: Interleukin 6; ISWT: Incremental Shuttle Walking Test; MRC: Medical Research Council Dyspnoea Grade; MFI 20: Multidimensional Fatigue Inventory; GF: General Fatigue Subscale; MF: Mental Fatigue Subscale; PF: Physical Fatigue Subscale; RA: Reduced Activity Subscale; RM: Reduced Motivation Subscale; RPE: Borg Rating of Perceived Exertion Scale; QoL: Quality of Life; SGRQ: Saint George's Respiratory Questionnaire; SpO2: Percutaneous Arterial Oxygen Saturation; Tq: Torque; % BW: Percentage of Body Weight.
This project was part of AL's PhD, which was in part funded by GlaxoSmithKline (GSK). RG has received honorariums and conference support from Pfizer, GSK, Hill-Rom and Boehringer Ingelheim (not specifically related to this study), PLB has no competing interests.
AL has contribution to conception and design, data collection and interpretation; PLB provided substantial contribution to interpretation of data, manuscript revision and RG participated in the design and manuscript writing. All authors read and approved the final manuscript.
The pre-publication history for this paper can be accessed here:
We gratefully acknowledge the contribution of GlaxoSmithKline UK and the Therapies Services of St. George's NHS Trust, London, UK to this research.